MX2021008966A - Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular. - Google Patents

Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular.

Info

Publication number
MX2021008966A
MX2021008966A MX2021008966A MX2021008966A MX2021008966A MX 2021008966 A MX2021008966 A MX 2021008966A MX 2021008966 A MX2021008966 A MX 2021008966A MX 2021008966 A MX2021008966 A MX 2021008966A MX 2021008966 A MX2021008966 A MX 2021008966A
Authority
MX
Mexico
Prior art keywords
increasing
phosphate compounds
tissular
perfusion
inositol phosphate
Prior art date
Application number
MX2021008966A
Other languages
English (en)
Spanish (es)
Inventor
Bestard Joan Perelló
Roca Carolina Salcedo
Mohamad Firas Bassissi
Reynés Miquel David Ferrer
Ferrer María Del Mar Pérez
Original Assignee
Sanifit Therapeutics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifit Therapeutics S A filed Critical Sanifit Therapeutics S A
Publication of MX2021008966A publication Critical patent/MX2021008966A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2021008966A 2019-01-30 2020-01-30 Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular. MX2021008966A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382061 2019-01-30
US201962913259P 2019-10-10 2019-10-10
PCT/ES2020/070070 WO2020157362A1 (en) 2019-01-30 2020-01-30 Inositol phosphate compounds for use in increasing tissular perfusion

Publications (1)

Publication Number Publication Date
MX2021008966A true MX2021008966A (es) 2021-11-04

Family

ID=69770927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008966A MX2021008966A (es) 2019-01-30 2020-01-30 Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular.

Country Status (11)

Country Link
US (2) US20220000889A1 (enExample)
EP (1) EP3917535A1 (enExample)
JP (2) JP2022521119A (enExample)
KR (1) KR20210148078A (enExample)
CN (1) CN113365636A (enExample)
AU (1) AU2020213713B2 (enExample)
BR (1) BR112021014897A2 (enExample)
CA (1) CA3130735A1 (enExample)
IL (1) IL285084A (enExample)
MX (1) MX2021008966A (enExample)
WO (1) WO2020157362A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3199478A1 (en) * 2020-11-20 2022-05-27 Vifor (International) Ag Inositol hexakisphosphate analogues for treatment of calcification associated kidney diseases
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
EP0632720B1 (en) 1992-03-25 1998-11-11 Depomed Systems, Inc. Hydroxyethylcellulose-based sustained-release oral drug dosage froms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
AU6912500A (en) * 1999-08-25 2001-03-19 Gmp Companies, Inc. Enhanced oxygen delivery in mammals, methods and reagents related thereto
WO2001024830A2 (en) * 1999-10-05 2001-04-12 Theramed, Inc. Incorporation of chemical substances into cells
JP2004510687A (ja) 1999-11-02 2004-04-08 ディポメド，インコーポレイティド 胃への薬剤投与の強化のための供給モードの薬理学的誘導
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
AU2001281071A1 (en) * 2000-08-01 2002-02-13 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
AU2001279118A1 (en) * 2000-08-01 2002-02-13 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP3678144B2 (ja) 2000-12-22 2005-08-03 ウシオ電機株式会社 フィルム回路基板の周辺露光装置
JP2004532259A (ja) 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
US9358243B2 (en) 2011-09-29 2016-06-07 Eth Zurich Pharmaceutical compounds for use in the therapy of Clostridium difficile infection
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
US10624909B2 (en) * 2015-12-11 2020-04-21 Eth Zurich Inositol derivatives for use in pathological crystallization
CN108368137B (zh) 2015-12-11 2020-11-13 苏黎世联邦理工学院 用于艰难梭状芽胞杆菌感染的4,6-二(邻硫代磷酸盐)-肌醇-1,2,3,5-四-邻硫酸盐

Also Published As

Publication number Publication date
CA3130735A1 (en) 2020-08-06
CN113365636A (zh) 2021-09-07
BR112021014897A2 (pt) 2021-09-28
AU2020213713A1 (en) 2021-07-22
EP3917535A1 (en) 2021-12-08
WO2020157362A1 (en) 2020-08-06
AU2020213713B2 (en) 2025-08-21
JP2024175025A (ja) 2024-12-17
JP2022521119A (ja) 2022-04-06
US20220000889A1 (en) 2022-01-06
IL285084A (en) 2021-09-30
US20230248749A1 (en) 2023-08-10
KR20210148078A (ko) 2021-12-07

Similar Documents

Publication Publication Date Title
ZA202306172B (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2022003984A (es) Compuestos heterociclicos antivirales.
PH12018501537A1 (en) Benzopyrazole compounds and analogues thereof
PH12015500313A1 (en) Orally administered medical composition
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2021006265A (es) Derivados de panteteina y usos de los mismos.
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MX2022009032A (es) Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.
TN2022000092A1 (en) Oral complement factor d inhibitors
BR112021022216A2 (pt) Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado
JOP20220076A1 (ar) مثبطات عامل d المكمل عن طريق الفم
TN2022000255A1 (en) Pyrrolopyrimidine amines as complement inhibitors
ZA202108034B (en) Crystalline salt forms of a kinase inhibitor
AR119159A1 (es) Tratamientos de angioedema
MX2021008966A (es) Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular.
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
BR112015012497A2 (pt) combinações farmacêuticas
CR20210043A (es) Forma de dosificación farmacèutica administrable por vía oral con liberación modificada
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
ZA202400679B (en) Dimethyl-substituted thiazololactam compound and use thereof
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
MX2020009334A (es) Compuestos para tratar la enfermedad de alzheimer.